Trial intelligence / Profile preview

Palliative short-course hypofractionated radiotherapy followed by FOLFOX chemotherapy in esophageal adenocarcinoma

2014-002362-74Phase 2Completed

Sponsor: Skåne University Hospital
Start: Jun 2014
Modality: Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of oxaliplatin, folinic acid and fluorouracil in esophageal adenocarcinoma (EAC) and gastroesophageal adenocarcinoma, sponsored by Skåne University Hospital. Primary endpoint: Improvement in dysphagia rate. Started Jun 2014; status: completed.

Drugs

oxaliplatinfolinic acidfluorouracil

Conditions

esophageal adenocarcinoma (EAC)gastroesophageal adenocarcinoma

Beyond the preview

Go deeper on 2014-002362-74.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2014-002362-74.